Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Gemma Whyatt, Jodi Whitehouse
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Operational description of rare diseases: a reference to improve the recognition and visibility of rare diseases
10.1186/s13023-024-03322-7 · 2024
Melanoma in congenital melanocytic naevi
10.1111/bjd.15301 · 2017
The role of surgery in the management of congenital melanocytic naevi in children: a perspective from Great Ormond Street Hospital
10.1016/j.bjps.2008.12.016 · 2009
Mental health challenges and psychosocial impact of rare diseases in children and adolescents -a systematic review
10.1007/s44162-026-00207-0 · 2026
10.70790/axuh4676
10.70790/axuh4676
Impact of public exhibition on the perception of birthmarks
10.1111/pde.15315 · 2023
MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children
10.1038/bjc.2017.49 · 2017
Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2
10.1111/bjd.20437 · 2021
Unresolved referenced work
Kept as external metadata until matched
How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration
10.1186/s13023-015-0281-2 · 2015
Data resource profile: the UK Cystic Fibrosis Registry
10.1093/ije/dyx196 · 2018
Data analytics from Enroll-HD, a global clinical research platform for Huntington’s disease
10.1002/mdc3.12388 · 2016
Data analytics from Enroll-HD, a global clinical research platform for Huntington’s disease
10.1002/mdc3.12388 · doi-reference
Data resource profile: the UK Cystic Fibrosis Registry
10.1093/ije/dyx196 · doi-reference
How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration
10.1186/s13023-015-0281-2 · doi-reference
Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2
10.1111/bjd.20437 · doi-reference
MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children
10.1038/bjc.2017.49 · doi-reference
Impact of public exhibition on the perception of birthmarks
10.1111/pde.15315 · doi-reference
10.70790/axuh4676
10.70790/axuh4676 · doi-reference
Mental health challenges and psychosocial impact of rare diseases in children and adolescents -a systematic review
10.1007/s44162-026-00207-0 · doi-reference
The role of surgery in the management of congenital melanocytic naevi in children: a perspective from Great Ormond Street Hospital
10.1016/j.bjps.2008.12.016 · doi-reference
Melanoma in congenital melanocytic naevi
10.1111/bjd.15301 · doi-reference
Operational description of rare diseases: a reference to improve the recognition and visibility of rare diseases
10.1186/s13023-024-03322-7 · doi-reference